Compare DOMH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | SNGX |
|---|---|---|
| Founded | 1967 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3M | 11.2M |
| IPO Year | 2010 | 2006 |
| Metric | DOMH | SNGX |
|---|---|---|
| Price | $3.37 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 227.9K | ★ 9.8M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | 34.03 | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $2.69 | $0.28 |
| 52 Week High | $8.40 | $6.23 |
| Indicator | DOMH | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 54.74 |
| Support Level | $2.80 | $0.28 |
| Resistance Level | $3.45 | $1.48 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 35.21 | 53.81 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).